Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1647
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18299877 | PHARMACEUTICAL COMPOSITIONS OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND METHODS OF USE | Non-Final OA | Hoffmann-La Roche Inc. |
| 18306038 | ICOS TARGETING FOR NEUROPATHIC PAIN RELIEF | Non-Final OA | Board of Regents, The University of Texas System |
| 18561347 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ADVANCED SOLID TUMORS | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | Non-Final OA | Gilead Sciences, Inc. |
| 18305667 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | Non-Final OA | VISTERRA, INC. |
| 18361179 | ANTI-GARP-TGF-BETA1/PD-1 COMBINATION THERAPY | Non-Final OA | AbbVie Deutschland GmbH & Co. KG |
| 18134854 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF TYPE I HYPERSENSITIVITY REACTIONS | Non-Final OA | IgGenix, Inc. |
| 18193958 | METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY | Non-Final OA | Servier Pharmaceuticals LLC. |
| 18189152 | SIRP-ALPHA FUSION POLYPEPTIDES WITH MODIFIED FC DOMAINS | Non-Final OA | Bitterroot Bio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy